{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:04:39Z","timestamp":1794956679195,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated the long term effects of IM in TGCT. We conducted an international multi-institutional retrospective study to assess the activity of IM: data was collected anonymously from individual patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States were identified. Four patients with metastatic TGCT progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable patients achieved complete response (CR) or partial response (PR). One- and five-year progression-free survival rates were 71% and 48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1\u201380) months. Reported adverse events in 45 (78%) patients were among other edema (48%) and fatigue (50%), mostly grade 1\u20132 (89%). Five patients experienced grade 3\u20134 toxicities. This study confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we confirmed prolonged IM activity on TGCT symptoms even after discontinuation, but with high rates of treatment interruption and additional treatments.<\/jats:p>","DOI":"10.1038\/s41598-019-51211-y","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T10:32:32Z","timestamp":1570703552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-5888","authenticated-orcid":false,"given":"F. G. M.","family":"Verspoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J. L.","family":"Mastboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hannink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9853-2528","authenticated-orcid":false,"given":"R. G.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-9448","authenticated-orcid":false,"given":"A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bompas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-9344","authenticated-orcid":false,"given":"J.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M.","family":"Seddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. T. A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-120X","authenticated-orcid":false,"given":"J.-Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Eberst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stacchiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A. J.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-1688","authenticated-orcid":false,"given":"P. A.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"issue":"6","key":"51211_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.semarthrit.2010.07.005","volume":"40","author":"S Ottaviani","year":"2011","unstructured":"Ottaviani, S., Ayral, X., Dougados, M. & Gossec, L. Pigmented Villonodular Synovitis: A Retrospective Single-Center Study of 122 Cases and Review of the Literature. Seminars in Arthritis and Rheumatism 40(6), 539\u2013546 (2011).","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"51211_CR2","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/rheumatology\/keu230","volume":"53","author":"FGM Verspoor","year":"2014","unstructured":"Verspoor, F. G. M. et al. Long-term follow-up results of primary and recurrent pigmented villonodular synovitis. Rheumatology (Oxford) 53, 2063\u20132070 (2014).","journal-title":"Rheumatology (Oxford)"},{"key":"51211_CR3","doi-asserted-by":"crossref","unstructured":"Ravi, V., Wang, W. L. & Lewis, V. O. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol (2011).","DOI":"10.1097\/CCO.0b013e328347e1e3"},{"key":"51211_CR4","unstructured":"de saint Aubain Somerhausen, N. & van de Rijn, M. Tenosynovial giant cell tumor, localized type\/diffuse type. In: WHO classification of tumors of soft tissue and bone (Eds Fletcher, C. D., Bridge, J. A., Hogendoorn, P. C. & Mertens, F.). Lyon: IARC Press, 100\u2013103 (2013)."},{"key":"51211_CR5","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.tripleo.2010.11.031","volume":"111","author":"HJ Yoon","year":"2011","unstructured":"Yoon, H. J., Cho, Y. A., Lee, J. I., Hong, S. P. & Hong, S. D. Malignant pigmented villonodular synovitis of the temporomandibular joint with lung metastasis: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111, e30\u201336 (2011).","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"51211_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-015-0030-2","volume":"5","author":"A Righi","year":"2015","unstructured":"Righi, A. et al. Metastasizing tenosynovial giant cell tumour, diffuse type\/pigmented villonodular synovitis. Clin Sarcoma Res 5, 15 (2015).","journal-title":"Clin Sarcoma Res"},{"key":"51211_CR7","first-page":"7402570","volume":"2017","author":"MJL Mastboom","year":"2017","unstructured":"Mastboom, M. J. L., Verspoor, F. G. M., Gelderblom, H. & van de Sande, M. A. J. Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases. Case Rep Orthop 2017, 7402570 (2017).","journal-title":"Case Rep Orthop"},{"issue":"10","key":"51211_CR8","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/rheumatology\/41.10.1113","volume":"41","author":"S Shabat","year":"2002","unstructured":"Shabat, S. et al. The use of surgery and yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints. Rheumatology 41(10), 1113\u20131118 (2002).","journal-title":"Rheumatology"},{"key":"51211_CR9","unstructured":"Heyd, R., Seegenschmiedt, M. H. & Micke, O. The Role of External Beam Radiation Therapy in the Adjuvant Treatment of Pigmented Villonodular Synovitis. Z Orthop Unfall (2011)."},{"key":"51211_CR10","doi-asserted-by":"publisher","first-page":"3072135","DOI":"10.1155\/2016\/3072135","volume":"2016","author":"FG Verspoor","year":"2016","unstructured":"Verspoor, F. G., Scholte, A., van der Geest, I. C., Hannink, G. & Schreuder, H. W. Cryosurgery as Additional Treatment in Tenosynovial Giant Cell Tumors. Sarcoma 2016, 3072135 (2016).","journal-title":"Sarcoma"},{"key":"51211_CR11","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2217\/fon.13.124","volume":"9","author":"FG Verspoor","year":"2013","unstructured":"Verspoor, F. G. et al. Pigmented villonodular synovitis: current concepts about diagnosis and management. Future Oncol 9, 1515\u20131531 (2013).","journal-title":"Future Oncol"},{"key":"51211_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1302\/0301-620X.96B8.33608","volume":"96-B","author":"L van der Heijden","year":"2014","unstructured":"van der Heijden, L., Mastboom, M. J., Dijkstra, P. D. & van de Sande, M. A. Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: a retrospective analysis of 30 patients. Bone Joint J 96-B, 1111\u20131118 (2014).","journal-title":"Bone Joint J"},{"issue":"3","key":"51211_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","volume":"103","author":"RB West","year":"2006","unstructured":"West, R. B. et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proceedings of the National Academy of Sciences of the United States of America 103(3), 690\u2013695 (2006).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"51211_CR14","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","volume":"31","author":"JS Cupp","year":"2007","unstructured":"Cupp, J. S. et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. American Journal of Surgical Pathology 31(6), 970\u2013976 (2007).","journal-title":"American Journal of Surgical Pathology"},{"key":"51211_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap, W. D. et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med 373, 428\u2013437 (2015).","journal-title":"N Engl J Med"},{"key":"51211_CR16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","volume":"16","author":"PA Cassier","year":"2015","unstructured":"Cassier, P. A. et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol 16, 949\u2013956 (2015).","journal-title":"Lancet Oncol"},{"key":"51211_CR17","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cncr.26409","volume":"118","author":"PA Cassier","year":"2012","unstructured":"Cassier, P. A. et al. Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis. Cancer 118, 1649\u20131655 (2012).","journal-title":"Cancer"},{"key":"51211_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-05-0359","volume":"5","author":"J Guo","year":"2006","unstructured":"Guo, J. et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 5, 1007\u20131013 (2006).","journal-title":"Mol Cancer Ther"},{"key":"51211_CR19","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1200\/JCO.2015.62.4304","volume":"33","author":"PG Casali","year":"2015","unstructured":"Casali, P. G. et al. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 33, 4276\u20134283 (2015).","journal-title":"J Clin Oncol"},{"key":"51211_CR20","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/ijc.25827","volume":"128","author":"M Essat","year":"2011","unstructured":"Essat, M. & Cooper, K. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int J Cancer 128, 2202\u20132214 (2011).","journal-title":"Int J Cancer"},{"key":"51211_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ctrv.2010.04.008","volume":"37","author":"H Joensuu","year":"2011","unstructured":"Joensuu, H., Trent, J. C. & Reichardt, P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 37, 75\u201388 (2011).","journal-title":"Cancer Treat Rev"},{"key":"51211_CR22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti, L. et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29, 1123\u20131132 (2015).","journal-title":"Leukemia"},{"key":"51211_CR23","doi-asserted-by":"crossref","unstructured":"Stephan, S. R., Shallop, B., Lackman, R., Kim, T. W. & Mulcahey, M. K. Pigmented Villonodular Synovitis: A Comprehensive Review and Proposed Treatment Algorithm. JBJS Rev 4 (2016).","DOI":"10.2106\/JBJS.RVW.15.00086"},{"key":"51211_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","volume":"51","author":"E Palmerini","year":"2015","unstructured":"Palmerini, E. et al. Tenosynovial giant cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur J Cancer 51, 210\u2013217 (2015).","journal-title":"Eur J Cancer"},{"key":"51211_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11864-015-0385-x","volume":"17","author":"M Brahmi","year":"2016","unstructured":"Brahmi, M., Vinceneux, A. & Cassier, P. A. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor\/Pigmented Villonodular Synovitis: Targeting the CSF1\/CSF1R Axis. Curr Treat Options Oncol 17, 10 (2016).","journal-title":"Curr Treat Options Oncol"},{"key":"51211_CR26","unstructured":"Mastboom, M. J. L. et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop, 1\u20137 (2017)."},{"key":"51211_CR27","doi-asserted-by":"crossref","unstructured":"Gelderblom, H. et al. An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. Proc Am Soc Clin Oncol 31 (suppl) (2013).","DOI":"10.1200\/jco.2013.31.15_suppl.10516"},{"key":"51211_CR28","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries, C. H. et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846\u2013859 (2014).","journal-title":"Cancer Cell"},{"issue":"15_suppl","key":"51211_CR29","doi-asserted-by":"publisher","first-page":"11502","DOI":"10.1200\/JCO.2018.36.15_suppl.11502","volume":"36","author":"William D. Tap","year":"2018","unstructured":"Tap, W. D. et al. Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT). ASCO Annual Meeting (2018).","journal-title":"Journal of Clinical Oncology"},{"key":"51211_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-018-0101-2","volume":"8","author":"N Giustini","year":"2018","unstructured":"Giustini, N., Bernthal, N. M., Bukata, S. V. & Singh, A. S. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature. Clin Sarcoma Res 8, 14 (2018).","journal-title":"Clin Sarcoma Res"},{"key":"51211_CR31","doi-asserted-by":"crossref","unstructured":"Sankhala, K. K. et al. A phase I\/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS). American Society of Clinical Oncology Conference: 2017 Annual Meeting ASCO. United States. 35 (15 Supplement 1) (2017).","DOI":"10.1200\/JCO.2017.35.15_suppl.11078"},{"key":"51211_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00204-011-0729-7","volume":"86","author":"E Thanopoulou","year":"2012","unstructured":"Thanopoulou, E. & Judson, I. The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol 86, 1\u201312 (2012).","journal-title":"Arch Toxicol"},{"key":"51211_CR33","doi-asserted-by":"crossref","unstructured":"Gelderblom, H. et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol (2018).","DOI":"10.1016\/S1470-2045(18)30143-8"},{"key":"51211_CR34","doi-asserted-by":"crossref","unstructured":"Verspoor, F. G. M. & Hannink, G. Systemic treatment of tenosynovial giant cell tumours in context. Lancet (2019).","DOI":"10.1016\/S0140-6736(19)30947-X"},{"key":"51211_CR35","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.suronc.2018.07.002","volume":"27","author":"MJL Mastboom","year":"2018","unstructured":"Mastboom, M. J. L. et al. Severity classification of Tenosynovial Giant Cell Tumours on MR imaging. Surg Oncol 27, 544\u2013550 (2018).","journal-title":"Surg Oncol"},{"key":"51211_CR36","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","volume":"38","author":"HL Gelhorn","year":"2016","unstructured":"Gelhorn, H. L. et al. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors. Clin Ther 38, 778\u2013793 (2016).","journal-title":"Clin Ther"},{"key":"51211_CR37","unstructured":"Verspoor, F. G. M. Tenosynovial Giant Cell Tunours: the good, the bad and the ugly PhD thesis, Radboud University Medical Center, https:\/\/repository.ubn.ru.nl\/bitstream\/handle\/2066\/196847\/196847.pdf (2018)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51211-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T14:31:22Z","timestamp":1671287482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51211-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["51211"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-51211-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]},"assertion":[{"value":"14 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RGM., AW., JYB., OM., PAC. received personal fees or honorarium for research support outside the submitted work as mentioned in the next paragraph and \u2018international committee of medical journal editors form for disclosure of potential conflicts of interest\u2019. All other authors received no financial support for the research and\/or authorship of this article. R.G.M. was in the advisory board of Novartis and received consulting fees at some point during the treatment of these patients. AW received consulting fees from Eli Lilly and Five Prime Therapeutics, also he reported research support from Plexxikon, Daiichi-Sankyo, Five Prime Therapeutics, Karyopharm, and Eli Lilly to the institution (Dana Farber Cancer Institute). JYB received grants and honoraria from Roche and Novartis (CentreL\u00e9on B\u00e9rard). BS was in advisory boards of Plexicon and Lily within the last 2 years. SS reported research grants from Novartis and Daiichi-Sankyo to the institution (Istituto Nazionale Tumori). OM received personal fees from Astra-Zeneca, Amgen, Bayer, BMS, Eli-Lilly, Novartis, Pfizer, Roche, and Servier outside the submitted work. MAJS reported research grants from Daiichi Sankyo and Implantcast to the institution (Leiden University Medical Center). WTAG reported a research grant from Novartis to the institution (Radboud University Medical Center). HG reported a research grant from Novartis and Daiichi to the institution (Leiden University Medical Center). PAC reports grants and personal fees from Novartis, Roche, Amgen; non-financial support from Plexxikon; grants, personal fees and non-financial support from Astra Zeneca during the conduct of the study; grants from Bayer, BMS, MSD, Toray, Taiho, BluePrint and from Eli Lilly outside the submitted work. The other authors (FGMV, MJLM, GH, EB, JD, AI, MB and LE) have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14551"}}